{
  "id": 1768145640319,
  "seqId": 73,
  "title": "Hyphaema Management: From Micro to 8-Ball",
  "summary": "An exhaustive clinical guide for the assessment, monitoring, and treatment of hyphaema, emphasizing trauma-related blood in the anterior chamber, high-risk features, and the management of secondary red cell glaucoma.",
  "date": "2026-01-11T15:34:00.319Z",
  "data": {
    "title": "Hyphaema Management: From Micro to 8-Ball",
    "summary": "An exhaustive clinical guide for the assessment, monitoring, and treatment of hyphaema, emphasizing trauma-related blood in the anterior chamber, high-risk features, and the management of secondary red cell glaucoma.",
    "summary_illustration": "<svg viewBox=\"0 0 100 100\" xmlns=\"http://www.w3.org/2000/svg\"><circle cx=\"50\" cy=\"50\" r=\"45\" fill=\"none\" stroke=\"#2c3e50\" stroke-width=\"2\"/><path d=\"M10 70 Q 50 60 90 70 L 85 85 Q 50 95 15 85 Z\" fill=\"#e74c3c\"/><line x1=\"50\" y1=\"15\" x2=\"50\" y2=\"35\" stroke=\"#3498db\" stroke-width=\"2\"/><circle cx=\"45\" cy=\"25\" r=\"1\" fill=\"#e74c3c\"/><circle cx=\"55\" cy=\"30\" r=\"1\" fill=\"#e74c3c\"/><circle cx=\"50\" cy=\"20\" r=\"1\" fill=\"#e74c3c\"/></svg>",
    "sections": [
      {
        "title": "Hyphaema: Core Definition",
        "icon": "info",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Blood in the aC is most commonly seen in the context of blunt trauma. It ranges from a relatively mild microhyphaema (erythrocytes suspended in the aqueous) to a total ‘8-ball’ hyphaema where the aC fill is complete (see Table 3.15 for assessment). HyPHaeMa [147]"
      },
      {
        "title": "Table 3.15 Specific features in assessment of hyphaema",
        "icon": "clinical_notes",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Category",
            "Assessment Details"
          ],
          "rows": [
            [
              "Hx",
              "Mechanism of injury (potential for IOFB, globe rupture), d Va (stable, worsening may suggest rebleed), sickle-cell status, risk factors, drug history (e.g. aspirin, nSaIDs, warfarin, etc.)"
            ],
            [
              "O/e",
              "note depth/distribution of hyphaema, IOP, iris trauma/abnormality (defer gonioscopy). Dilated fundoscopy: rule out any posterior segment injury"
            ],
            [
              "Ix",
              "Sickle-cell status. Consider B-scan uS and CT to rule out additional globe/orbital injuries (particularly if adequate clinical assessment not possible)"
            ]
          ]
        }
      },
      {
        "title": "Causes of Hyphaema",
        "icon": "account_tree",
        "type": "mindmap",
        "layout": "half_width",
        "color_theme": "purple",
        "content": {
          "center": "Etiology",
          "branches": [
            "Trauma: blunt or penetrating",
            "Surgery: e.g. trabeculectomy, iris manipulation procedures",
            "Spontaneous: iris/angle neovascularization, haematological disease, tumour (e.g. juvenile xanthogranuloma), IOL erosion of iris (uveitis–glaucoma–hyphaema (uGH) syndrome)"
          ]
        }
      },
      {
        "title": "Clinical Features & Complications",
        "icon": "visibility",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Erythrocytes in the AC: in minor bleeds, most erythrocytes fail to settle and are only visible with the slit-lamp (microhyphaema)",
          "Larger bleeds: result in a macroscopically visible layer (hyphaema)",
          "Complication: rebleeds",
          "Complication: corneal staining (especially if i IOP)",
          "Complication: red cell glaucoma"
        ]
      },
      {
        "title": "Box 3.4 High-risk features of hyphaema",
        "icon": "warning",
        "type": "red_flag",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "Children and others with i risk of non-compliance",
          "rebleed",
          "Large hyphaema (>1/3)",
          "Sickle-cell disease/trait",
          "On antiplatelets (e.g. aspirin) or anticoagulants (e.g. warfarin)",
          "Significant associated injury"
        ]
      },
      {
        "title": "Primary Treatment Strategy",
        "icon": "medication",
        "type": "process",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Step 1: admit high-risk cases (see Box 3.4)",
          "Step 2: Strict bed rest and globe protection (e.g. shield/glasses)",
          "Step 3: avoid aspirin/antiplatelet agents, nSaIDs, and warfarin, if possible (liaise with prescribing physician)",
          "Step 4: Topical steroid (e.g. dexamethasone 0.1% at least 4×/d)",
          "Step 5: cycloplegia (e.g. atropine 1% 1×/d)"
        ]
      },
      {
        "title": "Monitoring & Follow-up",
        "icon": "event_repeat",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Daily review (inpatient or outpatient) for IOP check and to rule out rebleeds while hyphaema resolving",
          "As improves, can be discharged and follow-up becomes less frequent",
          "From 2wk after resolution, patient can usually return to normal levels of activity",
          "From 2wk: gonioscopy ± indented indirect ophthalmoscopy can be performed",
          "Annual IOP checks (risk of angle recession glaucoma)"
        ]
      },
      {
        "title": "Red Cell Glaucoma Pathophysiology",
        "icon": "biotech",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "purple",
        "content": "Hyphaema (usually traumatic) leads to blockage of the trabecular mesh-work by red blood cells. In 10% of cases, a rebleed may occur, usually at about 5d. Patients with sickle-cell disease/trait do worse and are harder to treat (e.g. sickling may be worsened by acidosis from carbonic anhydrase inhibitors)."
      },
      {
        "title": "Management of Increased IOP",
        "icon": "medical_services",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Treatment of hyphaema: as described; see E Treatment, p. 146",
          "Topical agents: β-blocker, α-2-agonist, carbonic anhydrase inhibitor as required",
          "Systemic agents: e.g. acetazolamide, as required",
          "CONTRAINDICATION: avoid topical and systemic carbonic anhydrase inhibitors in sickle-cell disease/ trait",
          "Surgical: If medical treatment fails, consider aC paracentesis ± aC washout",
          "Surgical: If all else fails, trabeculectomy is an effective treatment",
          "Note: although trabeculectomy’s ‘life expectancy’ in these circumstances is short, it usually works long enough for the blood to clear"
        ]
      }
    ]
  },
  "chapterId": "trauma",
  "_serverSynced": true
}